Loading clinical trials...

Can Needle Size Improve Cancer Detection Rate of Transperineal MRI Target Prostate Biopsy Without Affecting Side Effects? | Clinical Trials | Clareo Health

RECRUITINGNA

Can Needle Size Improve Cancer Detection Rate of Transperineal MRI Target Prostate Biopsy Without Affecting Side Effects?

AOP2780 - Can Needle Size Improve Cancer Detection Rate of Transperineal MRI Target Prostate Biopsy Without Affecting Side Effects?

NCT06420115•University Hospital Padova

View on ClinicalTrials.gov

Summary

Differences in terms of diagnostic capability and side effects related to the needle caliber used for prostate biopsy sampling in patients with suspected prostate cancer

Detailed Description

To assess whether a larger caliber (16G) prostate biopsy needle increases the diagnostic capability of prostate neoplasia compared to a smaller caliber (18G) needle, while keeping perioperative complications constant.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Clinical suspicion of prostate cancer (presence of elevated prostatic specific antigen and/or suspicious digital rectal examination);
•Presence of at least one suspicious prostate lesion on MRI (Prostate Imaging-Reporting and Data System ≥ 3) according to the Prostate Imaging-Reporting and Data System v2.1 performed before Magnetic Resonance Imaging/transrectal ultrasound fusion biopsy.

Exclusion Criteria

•Patients under active surveillance or with a previous diagnosis of prostate neoplasia prior to biopsy.
•Previous radiotherapy to the prostate for neoplasia.

Locations (1)

Urology Unit - Padua University Hospital

Padua, Italy, Italy

Key Dates

Start Date

June 1, 2024

Primary Completion Date

December 1, 2025

Completion Date

May 30, 2026

Last Updated

March 25, 2025

Enrollment

580

ESTIMATED participants

Conditions

Prostate Cancer Diagnosis

Interventions

different needle size for prostate biopsy

DEVICE

Contacts

Fabio F. Zattoni, MD, PhD

CONTACT

0498212730 fabio.zattoni@unipd.it

Sponsors

Lead Sponsor

University Hospital Padova

Related Studies

Cognitive Fusion Prostate Biopsy With Biparametric Magnetic Resonance in the Detection of Prostate Cancer

NCT05818631

Prostate CancerProstate Cancer Diagnosis

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 25, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions